<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191525</url>
  </required_header>
  <id_info>
    <org_study_id>PROBIDEM</org_study_id>
    <nct_id>NCT04191525</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A 12 Week, Randomized, Double-blind, Placebo-controlled, Phase II Trial to Evaluate the Efficacy and Safety of the Treatment With BPL-1 in Adult Patients With Type 2 Diabetes Mellitus With Different Course of Disease and Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mónica Marazuela Azpíroz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alba Garcimartín Álvarez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Carolina Knott Torcal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nerea Aguirre Moreno</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Miguel Antonio Sampedro Núñez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>María Caldas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Belén Ruiz-Rosso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ana María Ramos Levi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes Mellitus type 2 (T2DM) is a chronic and progressive disease, characterized mainly by
      hyperglycemia. Metabolic imbalance causes an increased risk of microvascular and
      macrovascular complications associated with the increased prevalence of cardiovascular
      disease (CVD) in diabetics.

      Although genetic predisposition determines individual susceptibility to T2DM, external
      factors such as an unhealthy diet and a sedentary lifestyle condition the onset of the
      disease.

      Since T2DM is a multifactorial disease, many authors have studied the possible role of the
      microbiota and its alterations in the pathophysiology of the disease. There is evidence that
      in T2DM there are alterations in the proportion of Firmicutes, Bacteroidetes and
      Proteobacteria, and a smaller amount of bifidobacteria with anti-inflammatory properties.

      Probiotics are living microorganisms present in food that, if consumed in sufficient
      quantities, can improve health. In general, probiotics protect the patient through
      immunomodulation, protecting him from infections, increasing the activation of mononuclear
      cells and lymphocytes.

      The investigational product is a supplement to the probiotic Bifidobacterium animalis subsp.
      lactis (BPL-1) CECT 8145. There are numerous studies carried out on different strains of
      GLP-1 that demonstrate its safety. Many of them are commonly used in the food industry, not
      only because of their proven safety, but also because of their viability until consumption.

      This clinical trial is proposed as an interdisciplinary study that can contribute to the
      characterization of the efficacy of treatment with probiotics in patients with T2DM of
      different stages of evolution, without and with hepatic involvement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single-centre, randomized, double-blind clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fasting glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glycated haemoglobin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Glycated haemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Insulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>12 weeks</time_frame>
    <description>HOMA-IR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>HDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>LDL-cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>12 weeks</time_frame>
    <description>Triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Body Mass Index (BMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Fat Percentage (%BF)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Body Fat Percentage (%BF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist perimeter</measure>
    <time_frame>12 weeks</time_frame>
    <description>Waist perimeter</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mediterranean diet adherence score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mediterranean diet adherence score</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BPL-1 Probiotic capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BPL-1 Probiotic 1 capsule/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>BPL-1 Probiotic capsules</intervention_name>
    <description>BPL-1 Probiotic 1 capsule/day</description>
    <arm_group_label>BPL-1 Probiotic capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo masked with the same presentation as the experimental product 1 capsule/day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients between the ages of 18-75 (inclusive)

          -  BMI ≥ 27

          -  Glycated hemoglobin &gt; 5,6 and/or fasting glucose &gt; 100 mg/dl and/or being on active
             treatment with at least one antidiabetic medication

          -  Subjects must be able to provide written informed consent

          -  Females of childbearing potential must have a previous negative pregnancy test and
             must agree to use adequate contraception during their participation in the study

        Exclusion Criteria:

          -  Crohn's disease, liver cirrhosis, human immunodeficiency virus (HIV) or any other
             active systemic bacterial, viral or fungal infections

          -  BMI &gt; 42

          -  Severe hypoglycemias within 3 months prior to the start date of the study

          -  Abnormal glycated hemoglobin measurements (over 8%) prior to the start date of the
             study

          -  Prescription of a new antidiabetic medication in the last 6 months

          -  Celiac disease or any other food intolerances

          -  Use of antibiotics, probiotics and/or prebiotics within 2 weeks prior to the start
             date of the study

          -  Chronic liver disease with a C Child-Plug score, chronic kidney disease with
             creatinine clearance &lt; 50 ml/min as well as any other clinically significant
             conditions including pulmonary, neurological and cardiovascular diseases according to
             the investigators medical opinion

          -  Patients with history or presence of malignancy who have been treated with systemic
             antineoplastic therapy within 6 months prior to the start date of the study

          -  Pregnancy and breastfeeding

          -  Not being able to provide written informed consent to participate in the study or to
             cooperate and comply with the study procedures for any other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mónica Marazuela Azpíroz, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de La princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</investigator_affiliation>
    <investigator_full_name>Mónica Marazuela Azpíroz</investigator_full_name>
    <investigator_title>Head of Endocrinology and Nutrition</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Microbiote</keyword>
  <keyword>Cardiovascular Risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

